Newsroom

EDIMBURGO, Scozia--(BUSINESS WIRE)--RoslinCT, un'organizzazione globale di sviluppo e produzione a contratto (CDMO) specializzata in terapie cellulari avanzate, e BOOST Pharma, un'azienda biotecnologica di fase clinica che si dedica allo sviluppo di terapie cellulari innovative per malattie scheletriche rare in età pediatrica, hanno annunciato oggi l'avvio di una partnership di produzione strategica a sostegno dello sviluppo della terapia cellulare di BOOST Pharma, BT-101, per il trattamento di...

EDINBURGH, Schotland--(BUSINESS WIRE)--RoslinCT, een internationale CDMO (Contract Development & Manufacturing Organization) gespecialiseerd in geavanceerde celtherapieën, en BOOST Pharma, een biotechnologiebedrijf in klinische fase die uitstekende celtherapieën voor zeldzame pediatrische skeletaandoeningen ontwikkelt, maakten vandaag een strategisch productieakkoord bekend om de ontwikkeling van BT-101, BOOST Pharma’s celtherapie voor de behandeling van baby's met OI (Osteogenesis Imperfec...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Max Buffer UCITS ETF - September 07.01.2026 MSEP.LN IE0009DRFET8 150,002.00 USD 4,060,635.72 27.071  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Rising Dividend Achievers UCITS ETF 07.01.2026 RDVY LN IE000K5F6EL4 525,002.00 USD 11,919,194.33 22.703  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest Nasdaq-100 Moderate Buffer UCITS ETF - June 07.01.2026 QJUN.LN IE000HFBJ0U0 3,400,002.00 USD 73,632,455.50 21.657  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...

PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights Theoretical (1) Exercisable (2) December 31, 2025 2,206,585,543 2,206,585,543 2,142,883,014   (1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all the shares to which voting rights are attached, including shares for which voting rights have been suspended.   (2) Total number of exercisable vo...

PARIS--(BUSINESS WIRE)--Regulatory News: TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE) : Date Nombre d'actions composant le capital Nombre de droits de vote Théoriques (1) Exerçables (2) 31 décembre 2025 2 206 585 543 2 206 585 543 2 142 883 014   (1) Conformément à l’article 223-11 du règlement général de l’Autorité des Marchés Financiers, ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privées de droit de vote....

PARIS--(BUSINESS WIRE)--  TotalEnergies SE: Information Concerning the Total Number of Voting Rights and Shares in the Share Capital as at December 31, 2025 (Article L.233-8-II of the French Commercial Code and article 223-16 of the General Regulation of the AMF) TotalEnergies SE (Paris:TTE) (LSE:TTE) (NYSE:TTE): Date Total number of shares Number of voting rights Theoretical (1) Exercisable (2) December 31, 2025 2,206,585,543 2,206,585,543 2,142,883,014   (1) In accordance with Article 223-11...

NEW YORK & LONDON--(BUSINESS WIRE)--The post-war global order is fragmenting into spheres of influence as strongman leadership and transactional relationships replace multilateral cooperation, according to FGS Global's Radar 2026 report released today. FGS Global’s Radar is based on 175 in-depth interviews with senior global leaders and policy experts from the worlds of business, politics, academia and media and wide ranging, nationally representative polling of approximately 20,000 people acro...